The Center for Medicare and Medicaid Innovation today announced a new payment model for Medicare Part D and Medicare Advantage drug plans beginning January 2020, which will test new incentives for plans, patients and providers to choose drugs with lower list prices. Plans participating in the voluntary five-year model will take on greater risk for spending in the catastrophic phase of Part D and share in any resulting savings to federal reinsurance subsidy costs. The model also includes a Part D rewards and incentives program and other tools to help plans control drug costs and enrollees choose drugs with lower list prices. Also today, the Centers for Medicare & Medicaid Services announced changes to the MA Value-Based Insurance Design model for calendar year 2020, which will allow plans to provide reduced cost sharing and additional supplemental benefits to enrollees based on condition and/or socioeconomic status; bolster rewards and incentives for beneficiaries to improve their health; and increase access to telehealth services. 
 

Headline
The AHA shared the following statement with the media in response to a report released May 7 by Families USA.   “This report is long on rhetoric and…
Headline
The AHA May 7 wrote to House and Senate lawmakers in support of the Medicare Advantage Improvement Act (H.R. 8375/S. 4384), bipartisan and bicameral…
Headline
The Centers for Medicare & Medicaid Services announced May 6 that it will provide access to certain glucagon-like peptide-1 (GLP-1) medications to eligible…
Headline
The AHA today submitted comments on the Centers for Medicare & Medicaid Services’ proposed revisions to Medicare Advantage and Part D reporting…
Headline
The Centers for Medicare & Medicaid Services has begun collecting private payor rate data through its Fee-for-Service Data Collection System Clinical Lab…
Headline
Sens. Chuck Grassley, R-Iowa, and Michael Bennet, D-Colo., April 30 introduced the Rural Community Hospital Demonstration Reauthorization Act, legislation that…